In addition to suppressing classic proinflammatory mediators such as TNF-α, IL-6, and IL-17, AT-MSC-MVs also exert regulatory effects on IL-12 signaling, making them particularly suitable for treating IBD subtypes characterized by immune dysregulation [43,44,45,46]. This evidence concerns the gene IL6 and inflammatory bowel disease.